Angioplasty Balloons Market

The angioplasty balloons market is expected to increase from US$ 2.90 billion in 2024 to US$ 3.72 billion by 2031, achieving a CAGR of 3.6% during the period from 2025 to 2031.

Market Insights and Analyst Perspective:The forecast for the angioplasty balloons market provides valuable insights for stakeholders to strategize their growth. This report outlines growth opportunities, market trends, and their anticipated effects throughout the forecast period.

Angioplasty is a procedure aimed at widening narrowed or blocked coronary arteries to restore blood flow. The shift towards value-based care, which emphasizes cost-effectiveness and patient outcomes, is transforming the healthcare landscape. The angioplasty balloons market will be shaped by the ability of these devices to enhance patient outcomes, lower revascularization rates, and reduce costs compared to alternative treatments. Angioplasty balloons offer a less invasive approach to treating blocked arteries compared to traditional surgical methods. The demand for angioplasty balloons is increasing as both patients and healthcare providers favor less invasive options. The growing incidence of cardiovascular diseases and the rising preference for minimally invasive procedures are driving the expansion of the angioplasty balloons market. However, complications related to angioplasty may hinder market growth.

Growth Drivers:Rising Incidence of Cardiovascular Diseases Fuels Angioplasty Balloons Market

The World Health Organization (WHO) identifies cardiovascular diseases as the leading cause of morbidity and mortality globally. These diseases encompass cerebrovascular disease, coronary heart disease, and rheumatic heart disease. Key lifestyle factors contributing to cardiovascular diseases include tobacco use, poor diet, and lack of physical activity. The American Heart Association reported that cardiovascular disease-related deaths rose to 928,741 in 2020, up from 874,613 in 2019. In the US, coronary heart disease accounted for 41.2% of cardiovascular disease deaths in 2020, followed by stroke (17.3%), high blood pressure (12.9%), heart failure (9.2%), arterial diseases (2.6%), and other cardiovascular conditions (16.8%). The World Heart Federation anticipates over 23 million deaths annually due to cardiovascular diseases by 2030.

Additionally, cardiovascular risk factors are prevalent in Central and Western Europe, largely due to smoking and high alcohol consumption rates, particularly among men. Over 4 million Europeans die each year from cardiovascular diseases, primarily from coronary artery disease and stroke. The Middle East also experiences a high prevalence of cardiovascular diseases, necessitating various interventions such as health education, lifestyle counseling, screening, and treatment. According to the World Heart Federation, cardiovascular disease is the leading cause of death in the Middle East & North Africa, responsible for over a third of all deaths, totaling 1.4 million annually. Therefore, the increasing prevalence of cardiovascular diseases is a significant driver of growth in the angioplasty balloons market.

While angioplasty procedures are generally considered safe, there are reported complications that can arise during or after the surgery. Risks include blood clots, irregular heartbeats, damage to blood vessels or heart valves, strokes, allergic reactions to stent materials or drug-eluting stents, in-stent restenosis, or blockage of the stent's interior. Some of these risks can be life-threatening, and in certain situations, patients may not have sufficient time to undergo angioplasty, such as during a heart attack. These complications can impede the growth of the angioplasty balloons market.

Strategic Insights

Report Segmentation and Scope:The analysis of the angioplasty balloons market has been conducted by examining the following segments: type, application, and end user.

Segmental Analysis:In terms of type, the angioplasty balloons market is categorized into normal balloons, drug-eluting balloons, cutting balloons, and scoring balloons. The normal balloons segment held the largest market share in 2022. However, the drug-eluting balloons segment is projected to exhibit the highest CAGR from 2022 to 2030.

By application, the angioplasty balloons market is divided into peripheral and coronary segments. The coronary segment accounted for a larger share of the angioplasty balloons market in 2022 and is expected to show the highest CAGR during 2022-2030, driven by the rising incidence of coronary artery diseases, particularly heart disease. According to a March 2023 update from the Centers for Disease Control and Prevention (CDC), coronary heart disease is the most common type of heart disease, affecting about 1 in 20 individuals aged 20 and older. Nevertheless, the peripheral segment is anticipated to achieve a higher CAGR during 2022-2030.

Based on end user, the angioplasty balloons market is segmented into hospitals, ambulatory surgery centers, and cath labs. The hospitals segment held the largest market share in 2022 and is expected to register the highest CAGR from 2022 to 2030.

Regional Analysis:The geographic scope of the angioplasty balloons market report encompasses North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share in 2022, with growth driven by the increasing burden of an aging population, a rising number of product launches, and ongoing R&D efforts to develop advanced angioplasty balloons.

Angioplasty Balloons Market Report Scope

Competitive Landscape and Key Companies:Key companies profiled in the angioplasty balloons market report include Abbott, Boston Scientific Corporation, Cardinal Health, Cook Medical, C. R. Bard Inc, ENDOCOR GmbH, Medtronic, Spectranetics, BIOTRONIK, and Terumo Medical Corporation. These companies are focused on developing new technologies, enhancing existing products, and expanding their geographic reach to meet the growing global demand. Recent key developments include:

In March 2023, SIS Medical AG launched the OPN NC PTCA Dilatation Catheter with TWIN-Wall technology in the US, offering superior performance and safety with success rates where other balloons fail. The OPN NC catheter features a TWIN-Wall design that provides exceptional pressure resistance with a rated burst pressure of 35 atm and significantly low compliance.

In September 2022, Advanced NanoTherapies received Breakthrough Device Designation (BDD) from the FDA for its SirPlux Duo Drug-Coated Balloon (DCB) aimed at treating coronary artery disease. The SirPlux Duo DCB delivers a low-dose, long-term release of both compounds to inhibit cell growth, achieving maximum potency that surpasses any other DCB or drug-eluting stent.

In January 2022, the Scoreflex NC Scoring PTCA Catheter obtained Premarket Approval (PMA) from the US FDA. The Scoreflex NC is a scoring PTCA catheter indicated for the treatment of de novo stenotic portions of coronary arteries and in-stent restenosis in patients with coronary ischemia, aimed at improving myocardial perfusion.